ArticleScience translational medicine2023
A blood-based marker of mitochondrial DNA damage in Parkinson's disease.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 2 pooled it
15.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Mitochondrial quality control in neurodegenerative diseases: from molecular mechanisms to natural product therapies.Frontiers in physiology · 2025Pooled it
- Mitochondrial DNA (mtDNA) as fluid biomarker in neurodegenerative disorders: A systematic review.European journal of neurology · 2025Pooled it
- Profiling peripheral immune cells in Parkinson's disease: A scoping review.Journal of Parkinson's disease · 2026Review
- Long-read sequencing enables high-accuracy mitochondrial heteroplasmy detection in Parkinson's disease.BMC genomics · 2026Article
- Multi-omics approaches to parkinsonism: genomic, proteomic, and non-coding RNA perspectives.Molecular biology reports · 2026Review
- Prime editing in neuropsychiatric disorders: From mutation-specific target selection to clinical translation.Neuroprotection (Chichester, England) · 2026Review
- The vicious cycle: unraveling the interplay between α-synuclein, mitochondrial dysfunction, and neuroinflammation in Parkinson's disease.Journal of neurology · 2026Review
- Strategies for Optimizing Genetic Mouse Models to Enhance the Understanding of Parkinson's Disease.Biomedicines · 2026Review
- DAMP signaling networks: from receptors to diverse pathophysiological functions.Journal of advanced research · 2026Review
- Mitochondrial Fission and Fusion Disorders and Autophagy Abnormalities in Parkinson's Disease.Neurochemical research · 2026Review
- Rab12 is a regulator of mitophagy and mitochondrial homeostasis.bioRxiv : the preprint server for biology · 2026Article
- Mitochondrial DNA Damage in Substantia Nigra Pars Compacta Astrocytes Exacerbates Dopaminergic Neuron Loss in a 6-Hydroxydopamine Mouse Model of Parkinsonism.Cellular and molecular neurobiology · 2026Article
- Role of LRRK2 in physiological activities, diseases, and therapy.Chinese medical journal · 2026Review
- Towards biomarker-based diagnosis of Parkinson disease.Nature reviews. Neurology · 2026Review
- Parkinson's disease linked LRRK2 G2019S drives oxidative nuclear DNA damage and PARP1 hyperactive signaling.bioRxiv : the preprint server for biology · 2026Article
- Mitochondrial DNA: a molecular switch driving sterile neuroinflammation.Translational neurodegeneration · 2026Review
- Review
- Platelet mitochondrial complex I and IV activities are not reliable stratification biomarkers in Parkinson's disease.Journal of Parkinson's disease · 2025Article
- Label-free robotic mitochondrial biopsy.Science advances · 2025Article
- Investigating the ageing-Parkinson's disease nexus: standardisation of in vitro models and techniques by the PD-AGE network.NPJ Parkinson's disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 15 institutions in 6 countries.
Rui QiDepartments of Neurology and Pathology, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0009-0004-4852-373X
Esther SammlerMolecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK.ORCID 0000-0003-3218-7116
Claudia P Gonzalez-HuntDepartments of Neurology and Pathology, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-2736-0001
Ivana BarrazaDepartments of Neurology and Pathology, Duke University School of Medicine, Durham, NC 27710, USA.
Nicholas PenaDepartments of Neurology and Pathology, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0009-0008-1724-5641
Jeremy P RouanetDepartments of Neurology and Pathology, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-1800-9690
Yahaira NaaldijkDepartment of Anesthesiology and Department of Physiology, Pharmacology and Neuroscience, Rutgers New Jersey Medical School, Newark, NJ 07103, USA.ORCID 0000-0003-2701-3963
Steven GoodsonDepartments of Neurology and Pathology, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-2428-8371
Marie FuzzatiIRCCS Mondino Foundation, National Institute of Neurology, Pavia 27100, Italy.ORCID 0000-0002-6386-2885
Fabio BlandiniFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan 20122, Italy.ORCID 0000-0002-0178-1289
Kirk I EricksonDepartment of Psychology, University of Pittsburgh, Pittsburgh, PA 15213, USA.ORCID 0000-0001-8736-981X
Andrea M WeinsteinDepartment of Psychiatry, School of Medicine, University of Pittsburgh, PA 15213, USA.
Michael W LutzDepartments of Neurology and Pathology, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0001-8809-5574
John B KwokSchool of Medical Sciences, Faculty of Medicine and Health and the Brain and Mind Centre, University of Sydney, Camperdown, New South Wales 2050, Australia.ORCID 0000-0001-9574-6195
Glenda M HallidaySchool of Medical Sciences, Faculty of Medicine and Health and the Brain and Mind Centre, University of Sydney, Camperdown, New South Wales 2050, Australia.ORCID 0000-0003-0422-8398
Nicolas DzamkoSchool of Medical Sciences, Faculty of Medicine and Health and the Brain and Mind Centre, University of Sydney, Camperdown, New South Wales 2050, Australia.
Shalini PadmanabhanMichael J. Fox Foundation for Parkinson's Research, Grand Central Station, P.O. Box 4777, New York, NY 10120, USA.ORCID 0000-0002-6933-416X
Roy N AlcalayColumbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0000-0002-5717-4875
Cheryl WatersColumbia University Irving Medical Center, New York, NY 10032, USA.
Penelope HogarthDepartments of Molecular and Medical Genetics and Neurology, Oregon Health and Science University, Portland, OR 97239, USA.ORCID 0000-0003-1328-6311
Tanya SimuniFeinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.ORCID 0000-0002-2347-1644
Danielle SmithIndiana University School of Medicine, Indianapolis, IN 46202, USA.ORCID 0009-0005-7310-4999
Connie MarrasEdmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Canada.
Francesca TonelliMedical Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, DD1 5EH UK.ORCID 0000-0002-4600-6630
Dario R AlessiMedical Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, DD1 5EH UK.ORCID 0000-0002-2140-9185
Andrew B WestDuke Center for Neurodegeneration and Neurotherapeutics, Duke University, Durham, NC 27710, USA.ORCID 0000-0002-3034-4061
Sruti ShivaDepartment of Pharmacology and Chemical Biology and Medicine, Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA.ORCID 0000-0003-3535-2113
Sabine HilfikerDepartment of Anesthesiology and Department of Physiology, Pharmacology and Neuroscience, Rutgers New Jersey Medical School, Newark, NJ 07103, USA.ORCID 0000-0002-5167-7682
Laurie H SandersDepartments of Neurology and Pathology, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-1617-9562
Duke University · USThe University of Sydney · AUUniversity of Pittsburgh · USMRC Protein Phosphorylation and Ubiquitylation Unit · GBRutgers, The State University of New Jersey · USColumbia University Irving Medical Center · USIndiana University School of MedicineMichael J. Fox Foundation · USNinewells Hospital · GBNorthwestern University · USOregon Health & Science University · USTel Aviv University · ILToronto Western Hospital · CAUniversity of Pavia · ITUrology Foundation · GB
Funding
Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4MTREATMENT OF DEPRESSION IN ALZHEIMER'S DISEASEP50AG005133 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAMBOH, M. ILYAS · 1985 to 2019
$43.0MVARIABILITY, STABILITY & SMOOTHNESS OF WALKINGP30AG024827 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Caterina Rosano · 2004 to 2026
$28.6MMechanisms of LRRK2 Mediated NeurotoxicityR01NS064934 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WEST, ANDREW B · 2010 to 2025
$6.3MMechanisms of mitochondrial genome integrity in familial and idiopathic Parkinson's diseaseR01NS119528 · NINDS · DUKE UNIVERSITY · PI SANDERS, LAURIE H · 2020 to 2024
$2.9MIntraindividual Cognitive Variability as an Early Marker of Alzheimer's DiseaseK23AG076663 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Andrea Weinstein · 2022 to 2026
$915kThe Influence of an Exercise Intervention on Cognitive and Brain Health in ParkinF31NS089111 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WEINSTEIN, ANDREA · 2014 to 2016
$65kChief Scientist Office SCAF/18/01Medical Research Council MCUU12016/2NCATS NIH HHS UL1 TR002369NIA NIH HHS K23 AG076663NIA NIH HHS P30 AG024827NIA NIH HHS P50 AG005133NINDS NIH HHS F31 NS089111NINDS NIH HHS R01 NS064934NINDS NIH HHS R01 NS119528
Abstract
Parkinson's disease (PD) is the most common neurodegenerative movement disorder, and neuroprotective or disease-modifying interventions remain elusive. High-throughput markers aimed at stratifying patients on the basis of shared etiology are required to ensure the success of disease-modifying therapies in clinical trials. Mitochondrial dysfunction plays a prominent role in the pathogenesis of PD. Previously, we found brain region-specific accumulation of mitochondrial DNA (mtDNA) damage in PD neuronal culture and animal models, as well as in human PD postmortem brain tissue. To investigate mtDNA damage as a potential blood-based marker for PD, we describe herein a PCR-based assay (Mito DNA
Indexed as
DNA, MitochondrialParkinson DiseaseAnimalsDNA DamageHumansLeukocytes, MononuclearMiceMitochondriaRatsDNA, Mitochondrial
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.